secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001193125-26-003506
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics receives FDA 'Study May Proceed' letter for (Z)-Endoxifen metastatic breast cancer trial
--------------------------------------------------------------------------------

- FDA issued 'Study May Proceed' letter for Atossa's IND for (Z)-Endoxifen in metastatic ER+/HER2- breast cancer.
- Trial will evaluate (Z)-Endoxifen in tumors resistant to other endocrine therapies; targets PKCβ1 pathway.
- CEO Dr. Steven Quay calls this an important regulatory milestone to expand (Z)-Endoxifen's potential use.
- (Z)-Endoxifen is a potent SERM/D with distinct pharmacology from tamoxifen; not yet approved for any indication.
- Program backed by growing global IP portfolio including issued U.S. patents and pending applications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526003506/0001193125-26-003506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526003506/atos-20260106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-003506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer